ATE431748T1 - Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren - Google Patents

Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren

Info

Publication number
ATE431748T1
ATE431748T1 AT01980694T AT01980694T ATE431748T1 AT E431748 T1 ATE431748 T1 AT E431748T1 AT 01980694 T AT01980694 T AT 01980694T AT 01980694 T AT01980694 T AT 01980694T AT E431748 T1 ATE431748 T1 AT E431748T1
Authority
AT
Austria
Prior art keywords
nucleic acids
combination
sugar
administration
formulations containing
Prior art date
Application number
AT01980694T
Other languages
English (en)
Inventor
Susan Conroy
Heidrun Engler
Daniel Maneval
Original Assignee
Innovata Ltd
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0026892A external-priority patent/GB0026892D0/en
Priority claimed from GB0110525A external-priority patent/GB0110525D0/en
Priority claimed from GB0112585A external-priority patent/GB0112585D0/en
Application filed by Innovata Ltd, Canji Inc filed Critical Innovata Ltd
Application granted granted Critical
Publication of ATE431748T1 publication Critical patent/ATE431748T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Saccharide Compounds (AREA)
AT01980694T 2000-11-03 2001-11-02 Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren ATE431748T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0026892A GB0026892D0 (en) 2000-11-03 2000-11-03 Nucleic acid delivery
GB0110525A GB0110525D0 (en) 2001-04-30 2001-04-30 Nucleic acid delivery
GB0112585A GB0112585D0 (en) 2001-05-24 2001-05-24 Nucleic acid delivery
PCT/GB2001/004878 WO2002036167A1 (en) 2000-11-03 2001-11-02 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids

Publications (1)

Publication Number Publication Date
ATE431748T1 true ATE431748T1 (de) 2009-06-15

Family

ID=27255959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980694T ATE431748T1 (de) 2000-11-03 2001-11-02 Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren

Country Status (10)

Country Link
EP (1) EP1330265B1 (de)
JP (1) JP4426757B2 (de)
AT (1) ATE431748T1 (de)
AU (2) AU1248602A (de)
CA (1) CA2426334C (de)
DE (1) DE60138762D1 (de)
ES (1) ES2327491T3 (de)
MX (1) MXPA03003983A (de)
NZ (1) NZ525362A (de)
WO (1) WO2002036167A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
BRPI0515819A (pt) * 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado
EA034858B1 (ru) * 2015-01-30 2020-03-30 Фрезениус Каби Дойчланд Гмбх Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233715B1 (de) * 1986-01-31 1994-05-25 BEECHAM GROUP plc Isolierung und Expression von bei der Biosynthese von Beta-Laktamen beteiligten Genen
DE19748290B8 (de) * 1997-10-31 2009-09-03 Fresenius Medical Care Deutschland Gmbh Lösung für die Peritonealdialyse
MXPA02001472A (es) * 1999-08-10 2002-07-02 Ml Lab Plc Metodo para suministrar agentes terapeuticos utilizando una solucion de dextrina.

Also Published As

Publication number Publication date
AU2002212486B2 (en) 2007-10-04
DE60138762D1 (de) 2009-07-02
EP1330265B1 (de) 2009-05-20
CA2426334C (en) 2011-09-20
EP1330265A1 (de) 2003-07-30
JP4426757B2 (ja) 2010-03-03
WO2002036167A1 (en) 2002-05-10
MXPA03003983A (es) 2003-08-19
AU1248602A (en) 2002-05-15
NZ525362A (en) 2004-11-26
WO2002036167A8 (en) 2002-09-26
CA2426334A1 (en) 2002-05-10
JP2004512380A (ja) 2004-04-22
ES2327491T3 (es) 2009-10-30

Similar Documents

Publication Publication Date Title
BR9910251A (pt) Estimulação hematopoiética
ATE429210T1 (de) Orale flüssige zusammensetzungen
EP1325019A4 (de) Antisense-modulation der clusterinexpression
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
MY135913A (en) Fsh and fsh variant formulations comprising benzyl alcohol as a preservative
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
AU2001254624A1 (en) Human coagulation factor vii variants
AU2002214596A1 (en) Methods and compositions for nucleic acid delivery
EP1409506A4 (de) Verfahren und zusammensetzungen zur rnai vermittelten inhibierung der genexpression in säugetieren
TR200101400T2 (tr) 2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
DE60038011D1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
WO2004011060A3 (en) Delivery of molecules and complexes to mammalian cells in vivo
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
BR0213298A (pt) formulações com alta concentração de proteìna e processo de fabricação
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
EP1583836A4 (de) VERFAHREN ZUR EINFÜHRUNG VON siRNA IN ADIPOZYTEN
WO2003092612A3 (en) VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
BR0014519A (pt) Sequências de sinais para a preparação de leu-herudin através da secreção por e. coli no meio de cultura
DE60138762D1 (de) Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren
ATE418272T1 (de) Enzymbehandelter ahornsirup, nur auf ahornsirup basierende, haltbare produkte, und ahornsirup- mischprodukte
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
EP1248633A4 (de) Antisense-modulation der expression von glycogen-synthase kinase 3 beta
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties